NIPPON KAYAKU CO.,LTD. [4272.T]
TOKYO, May 25 (Pulse News Wire) – Nippon Kayaku CO.,LTD. (4272.T) has entered into a contract with AstraZeneca Co., Ltd.
For the succession of manufacturing and selling rights for Zoladex® 3.6 mg Depot/LA 10.8 mg Depot in Japan. Under this agreement, NIPPON KAYAKU, which has established a robust track record and solid foundation in the domestic market, will take over the production and sales of the drug, aiming to optimize its lifecycle and ensure stable long-term supply. The transition period for the manufacturing and sales approval will be communicated once finalized.
The anticipated impact of this succession was already reflected in the company's forecasted annual performance for the fiscal year ending March 2027, announced on May 12, 2026. Therefore, this release does not affect the current fiscal year’s earnings outlook. However, should there be any significant future developments related to contract execution or market trends, additional disclosures will be made accordingly.
Via telephone at 03-6,731-5237.
🟢 Confidence: High AI-translated content.